Previous Speakers

Scott Umlauf

Senior Director, Product Development VaxInnate Corporation USA

Richard Colonno

Assembly Biosciences USA

Vadim Bichko

Vice President and Head, Infectious Diseases at ChemDiv Inc. USA

Marek Malecki

Phoenix Biomolecular Engineering Foundation USA

Uri Galili

UMass Medical School USA

Diane Beylkin

SRI International USA

Kai Mckinstry

University of Central Florida USA

Tara Strutt

University of Central Florida USA

Recommended Global Infectious Diseases Conferences

Flu and Infectious Diseases 2017

About Conference

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Flu 2016, ConferenceSeries Ltd is delighted to announce the next event

Conference Series invites all the participants from all over the world to attend 3^rd International Conference on Flu & Emerging Infectious Diseases during November 06-07, 2017 at Las Vegas, USA.

The field of Flu & Emerging Infectious Diseases is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

World Flu & Emerging Infectious Diseases 2017

Opportunity to attend the presentations delivered by eminent scientists from all over the world. Selected contributions will be published in following Conference Series Journals

· Virology & Mycology

· Virology & Antiviral Research

· Journal of Vaccines & Vaccination

Participation in sessions on specific topics on which the conference is expected to achieve progress

Global networking: In transferring and exchanging Ideas

Conference brings together Scientific Researchers, Virologists, Immunologists, Microbiologists, Pathologists, Infectious Diseases Specialists, Health Care Professionals and Physicians

Sessions/Tracks

Track 1: Emerging Infectious Diseases

Infectious disease whose incidence in human has increased in the past 2 decades (or) threatens to be in the near future have been defined as " Emerging". These diseases include new infections, previously nonrecognized infections and old infections reappearing due to antimicrobial resistance and public health issues due to unhygienic conditions.

Related Conference

2^nd Annual Conference on Rare Diseases and Orphan Drugs, Oct 30- Nov 1, 2017, San Antonio USA; 4^th Euro-Global Conferences on Infectious Diseases, during September 07-09, 2017, Paris, France; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; 5th International Congress on Bacteriology and Infectious Diseases, May 25-26, 2017 Chicago, Illinois, USA; International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada; Sixth International Conference on Infectious Disease Dynamics 29 November-1 December, 2017 Sitges (near Barcelona), Spain; 35^th Annual Infectious Diseases Conference, February 3-4, 2017 Sacramento, CA, United States; 24^th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017 Seattle, USA; 27th European Congress of Clinical Microbiology and Infectious Diseases, April 22-25, 2017 Vienna, Austria.

Track 2: Global Distribution And Transmission of Emerging infectious disease

The extent of the global burden of infectious diseases depends on the already prevailing incidences and prevalences of familiar infections together with the consistent, but uneven, flow of emerging and reemerging infections. Infectious diseases emerging throughout history have included some of the most dangerous plagues of the past. As new infections continue to emerge today, while many of the old plagues are still with us. Infectious disease can be transmitted by person to person by direct or indirect contact where Micro-organisms, viruses ,fungi and parasites are most common source of transmission.

Related Conference

4^th International Conference on Sexually Transmitted Diseases, Jun 19-20, 2017 UK ;International Conference on Vector Borne Diseases ,June 29-30, 2017 Philadelphia, USA; 2^ndInternational Conference on Flu,Oct 31- Nov 2, 2016 in San Francisco, USA; 3rd International Conference on Retroviruses and Novel Drugs ,July 27-28, 2017 Vancouver, Canada; UK;3^rd World Congress on Infectious Diseases ,Aug 21-23, 2017 California, San Francisco, USA; 24^th Conference on retroviruses and opportunistic infections Feb 13-16, 2017 USA; Keystone Symposia-Malaria: From innovation to eradication, Feb 19-23, 2017 Uganda; Australasian society for infectious diseases annual scientific meeting, Mar 29-Apr 01, 2017; ICHA 2017: 19^th International Conference on HIV and AIDS ,May 25-26, 2017 London, UK; STI & HIV World Congress ,July 9-12, 2017 Rio de Janeiro, Brazil.

Track 3: Factors In The Emergence Of Infectious Diseases

Most of the emerging infections appear to be caused by pathogens already present in the environment, brought out of obscurity or given a selective advantage by changing conditions and afforded an opportunity to infect new host populations. The process by which infectious agents may transfer from animals to humans or disseminate from isolated groups into new populations can be called microbial traffic. A number of activities increase microbial traffic and as a result promote emergence and epidemics.

Related Conference

Track 4: Host Defences Against Infectious Diseases

For preventing infectious diseases the human body has several general mechanisms. Some of these mechanisms are referred to as nonspecific defenses because they operate against a wide range of pathogens. Some of the other mechanisms are referred to as specific defenses because they target particular pathogens and pathogen-infected cells.

Related Conference

Track 5: Public Health Measures To Prevent Emerging Infectious Diseases

Developed countries have regulations that help to protect the general public from infectious diseases. Public health measures typically involve eliminating the pathogen from the reservoir or from its route of transmission. The measures include ensuring a safe water supply, effectively managing sewage treatment and disposal, and initiating food safety, animal control, and vaccination programs.

Related Conference

Track 6: Treatment For Emerging Infectious Diseases

The word “Antibiotic” has become the most commonly used word to refer to a chemical substance used to treat bacterial infections. The term "antimicrobial" usually refers to anything that prevents the growth of microbes. Technically, the term antimicrobial does not encompass the "antihelminthic" drugs because parasitic worms are not microscopically small. Antimicrobials can be either microbistatic or microbicidal.

Related Conference

Track 7: Flu /Influenza Virus

Influenza viruses are among the most common causes of human respiratory infections, and are also among the most significant because they cause high morbidity and mortality. Influenza outbreaks have apparently occurred since at least the Middle Ages. In the elderly, in infants, and in people with chronic diseases, influenza is associated with especially high mortality. In the United States, flu results in approximately 200,000 hospitalizations and 36,000 deaths in a typical endemic season.

Related Conference

Track 8: Antigenic Variation Of Flu/ Influenza Virus

The explosive nature of epidemic flu and the specific clinical features of this disease have given definitive epidemiological records of this infection since the beginning of the nineteenth century. Some of the epidemics were recorded during the nineteenth century but the first pandemic was not precisely recorded until 1889-92. A second pandemic, probably originating in Europe, occurred in 1918-19, and is called as Spanish Influenza. It is responsible for 20-25 million deaths, principally in young adults. It was suggested that this strain had unusual virulence.

Related Conference

Track 9: Pathology Of Flu/ Influenza Virus

When flu virus is driven into the respiratory tract by aerosol or by contact with saliva or other respiratory secretions from an affected individual, it attaches and replicates in epithelial cells. The virus replicates in cells of both the lower and upper respiratory tract. Viral replication combined with the immune response to infection lead to destruction and loss of cells lining the respiratory tract.

Related Conference

Track 10: Symptoms And Treatment Of Flu/Influenza Virus

There are three types of influenza viruses affect people, called Type A, Type B, and Type C. Approximately 33% of people with influenza are asymptomatic. The symptoms of influenza can start quite suddenly one to two days after infection. Fever and extreme coldness , Cough, Nasal congestion, Vomiting, Runny nose, Sneezing, Body aches, especially joints and throat, Fatigue, Headache, skin (especially face), Petechial rash. People with the flu are advised to medications such as acetaminophen (paracetamol) to relieve the fever and muscle aches associated with the flu. Antiviral medication may be effective, if given early, but some strains of influenza can show resistance to the standard antiviral drugs.

Related Conference

Track 11: Flu/ Influenza Vaccines And Vaccination

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use . The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

Related Conference

Track 12: Flu/ Influenza Vaccines And Vaccination

Influenza vaccines, also known as flu shots or jabs, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk.

Related Conference

Track 13: Antivirals and Therapeutics For Flu disease

Antiviral drugs are prescription medicines that fight agaist the flu in your body. The two classes of antiviral drugs used against influenza are neuraminidase inhibitors (oseltamivir and zanamivir) and M2 protein inhibitors (adamantane derivatives). Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products(EMEA), now a days force developers as well as manufacturers to improve their production and purification processes for viral vectors and vaccines.

Related Conference

Track 14: Flu Vaccines And Case Reports Of Flu

Influenza drug effectivity is evaluated in clinical trials conducted within the setting of current, naturally occurring influenza illness. However, a drug effective within the treatment of seasonal influenza might not be effective or as effective in pandemic influenza or in sporadic cases caused by alternative novel strains. Avian influenza, listed by the World organisation for Animal Health (OIE), has become a illness of nice importance for animal and human health.

Related Conference

Track 15: Flu Virus -Advancements In Detection & Differentiation

Influenza outbreaks and epidemics constitute ongoing risks to global human public health. Recently, human infections with A/H5N1 avian influenza viruses have intensified the potential for the emergence of an influenza A virus with pandemic potential. Laboratory identification of human influenza virus infections is commonly performed using virus isolation in cell culture, direct antigen detection, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR). In recent years commercial influenza rapid diagnostic tests have become available which are antigen detection tests that produce results within 30 minutes. They can provide results in a clinically relevant time frame to complement the use of antiviral medications for treatment and chemoprophylaxis of influenza.

Related Conference

Track 16: Epidemology and Public Health of Flu/ Influenza

Public health epidemiologic investigations and surveillance are critical public health functions for identifying threats to the health of a community. In an emergency, public health surveillance is the on going systematic collection, analysis, interpretation, and management of public health-related data to verify a threat or incident of public health concern, and to characterize and manage it effectively through all phases of the incident. Surveillance data is used to identify and monitor the arrival of influenza, its geographic spread, intensity of activity, characteristics of those infected, as well as severity and changing trends in order to guide prevention and control recommendations.

Related Conference

Market Analysis Report

Importance & Scope:

Flu is an infectious disease caused by the influenza virus. Influenza is a highly contagious disease affecting almost all mammals and birds. Flu occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Illnesses can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically ill). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths.

Experts from various fields like virology, medicine, immunology, microbiology, public health planning, epidemiology, pharmacology and vaccinology all work on the flu virus.

The infectious diseases therapeutic market in US is estimated to grow at a rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to infectious diseases globally. Current market trend shows that North America has the more global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market.

USA

CDC monitors the hospitalizations associated with laboratory-confirmed influenza virus infections Among 9,586 cases with influenza type specified, 8,497 (88.2%) were associated with influenza A virus infection, 1,046 (10.9%) with influenza B virus infection, and 43 (0.4%) were associated with mixed influenza A and influenza B virus infections. Persons aged 18–64 years accounted for 57.4% of reported hospitalizations. The cumulative incidence for all age groups for the period October 1, 2013–April 30, 2014, was 35.6 per 100,000 (Figure 3). The cumulative hospitalization rate (per 100,000 population) by age group for this period was 46.9 (for 0–4 years), 9.5 (5–17 years), 22.0 (18–49 years), 54.3 (50–64 years), and 88.1 (≥65 years).

Market for Flu and Emerging Infectious Diseases Research:

The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.

The Infectious disease diagnostic (IDD) market is estimated to grow at a CAGR of 7.9% to reach $18,156.2 million by 2019. Traditional diagnostic techniques such as immunodiagnostics and biochemical characterization are the largest segments of the IDD market. However, molecular diagnostic techniques, such as microarrays and isothermal nucleic acid amplification technology (INAAT), will show the fastest growth in the forecast period.

Why Las Vegas:

Emerging Infectious diseases are among the most challenging issues facing health care delivery systems around the world today. The World Health Organisation estimates that more than 17 million people die of an infectious disease each year, with many of these acquired in hospitals. Thus not only is it imperative to have rapid and efficient tests for countries in the developing world, healthcare providers in developed countries can also benefit. The situation in developed countries is probably less urgent for the tropical diseases, but it is equally important to have better rapid tests for hepatitis, HIV, tuberculosis and sexually transmissible diseases worldwide.

Fund Allotment to Flu Research:

The US government awarded five-year contracts for more than $1 billion to five drug manufacturers developing technology for speedier mass production of vaccines in the event of a pandemic from the $3.8 billion pandemic preparedness bill passed in 2005. Currently, flu vaccines are produced in specialized chicken eggs, but that technique does not allow for speedy mass vaccinations." The companies receiving the contracts were:

GlaxoSmithKline $274.8 million
Medimmune Inc $169.5 million
Novartis Vaccines and Diagnostics $220.5 million
DynPort Vaccine Company,LLC $41 million
Solvay Pharmaceuticals $298.6 million

The US government purchased from Sanofi Pasteur and Chiron Corporation several million doses of vaccine in case of an influenza pandemic due to H5N1 and is conducting clinical trials on them. ABC News reported that Beginning in late 1997, the human trials have tested 30 different vaccines, all pegged to the H5N1 virus.

For H9N2 threat, NIAID contracted with Chiron Corporation to produce investigational batches of an inactivated vaccine, which will be evaluated clinically by NIAID early next year^.For H5N1, Aventis-Pasteur and Chiron are both producing investigational lots of inactivated H5N1 vaccine preparations additionally, DHHS has contracted with Aventis to produce up to 2 million doses to be stockpiled for emergency use, if needed, to vaccinate health workers, researchers, and, if indicated, the public in affected areas. Development and evaluation of a combination antiviral regimen against these potential pandemic influenza strains are also now under way.

According to Global Pandemic Influenza Preparedness Markets, their size, trends and drivers, principally for the countries with health expenditures per capita exceeding $2,000. The results of this study found that since outbreaks of bird flu in 2005 and swine flu in 2009, the governments had recognized antiviral pandemic stockpiling as their preferred strategy for disease containment and mitigation. Market Research Media has found that over the past five years, government spending worldwide on Pandemic Influenza Preparedness has more than tripled from $2.2 billion in 2004 to $7 billion in 2009, at a 17% CAGR. Market Research Media forecasts that worldwide government spending on Pandemic Influenza Preparedness will continue to grow, though at more moderate rate of a 5% CAGR, reaching almost $10 billion by 2015.

The HHS announces funding of about $1 billion for clinical studies that will take place over the next few months and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.

The following companies will receive funding to produce H1N1 vaccine ingredients:

Novartis AG – $289 million,
Sanofi Aventis SA – $191 million,
GlaxoSmithKline PLC – $181 million,
Another $150 million will be directed to produce pilot lots of vaccine and to fund the clinical studies.

Reference:

Past Conference Report

Flu-2016

Conference series LLC hosted the “2^nd International Conference on Flu” during October 31-November 02, 2016 at DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, USA with the theme “Scientific Milestones in Understanding and Preventing Flu” where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.

Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Virologists, scientists, researchers, students and leaders in Flu Research, who made this event successful.

The Conference was carried out through various informative and cutting edge sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

Flu Vaccines: Current and Novel Approach
Pathology of Influenza Virus Infections
Flu Symptoms & Treatment
Antivirals and Therapeutics
Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups
Flu Virus -Advancements in Detection & Differentiation
Flu: Immunology & Genetics
Flu Clinical Studies & Case Reports
Epidemiology and Public Health of Influenza
Surveillance Issues and Burden of Disease

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

Donald P Francis, Global Solutions for Infectious Diseases, USA
Ananda M Chakrabarty, University of Illinois College of Medicine, USA
Anthony S Gilbert, hVIVO, UK
Palayakotai Raghavan, Nanorx Inc, USA
Manon M J Cox, Protein Sciences, USA
Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA
Sunil K Lal, Monash University, Malaysia

All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Jun Wang, University of Arizona, USA and Sunil K Lal, Monash University, Malaysia for his remarkable contribution towards smooth functioning at Flu-2016 Conference.

Conference Sessions Chairs:

Donald P Francis, Global Solutions for Infectious Diseases, USA
Palayakotai Raghavan, Nanorx Inc, USA
Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA

Conference Series LLC offers its heartfelt appreciation to Societies and Organizations includes Allied Academies, Andrew John Publishing Inc., New York Private Equity Forums and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series LLC in supporting and making the conference a never before one.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph Flu-2016, Conference Series LLC is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, "3^rd International Conference on Flu & Emerging Infectious Diseases" to be held during Oct 30-Nov 01, 2017 at Las Vegas, USA.

Let us meet again @ Flu-2017

Past Reports Proceedings Gallery

To Collaborate Scientific Professionals around the World

Conference Date November 06-07, 2017

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Flu-2016 Report Flu-2016 Proceedings Flu-2016 Conference

Supported By

Virology & Mycology Journal of Virology & Antiviral Research Journal of Vaccines & Vaccination Journal of Clinical & Cellular Immunology

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by

Flu and Emerging Infectious Diseases

November 06-07, 2017 Las Vegas, Nevada, USA

Theme: Understanding the Flu and Infectious Diseases; Risk Analysis and Prevention

Conference Series Conferences gaining more Readers and Visitors

Previous Speakers

Scott Umlauf

Richard Colonno

Vadim Bichko

Marek Malecki

Uri Galili

Diane Beylkin

Kai Mckinstry

Tara Strutt

Recommended Global Infectious Diseases Conferences

USA & Americas

Europe & UK

Asia Pacific & Middle East

Flu and Infectious Diseases 2017

About Conference

Sessions/Tracks

Market Analysis Report

Past Conference Report

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By